Synapse Technologies Overview

  • Founded
  • 1992
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $15.3M
Latest Deal Amount

Synapse Technologies General Information

Description

Developer of proprietary technology to deliver therapeutic enzymes and other drugs. The company focuses on discovery, development and commercialization of transport systems for therapeutic drug delivery across the blood brain barrier and new drug targets in neurodegenerative disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Primary Office
  • 6660 NorthWest Marine Drive
  • Vancouver, British Columbia B6T 1Z4
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Synapse Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 21-Mar-2002 $15.3M 000 000.00 Completed Clinical Trials - General
1. Later Stage VC 12-Jan-2000 000 000 Completed Startup
To view Synapse Technologies’s complete valuation and funding history, request access »

Synapse Technologies Executive Team (1)

Name Title Board Seat Contact Info
Z Ruttonsha Chief Executive Officer & President
To view Synapse Technologies’s complete executive team members history, request access »

Synapse Technologies Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BDC Capital Venture Capital Minority 000 0000 000000 0
BMO Financial Group Lender/Debt Provider Minority 000 0000 000000 0
FutureFund Capital Venture Capital Minority 000 0000 000000 0
GrowthWorks Venture Capital Minority 000 0000 000000 0
MDS Ventures Pacific Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »